Literature DB >> 18417963

Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients.

Robert Gan1, Caroline Lambert, Jiao Lianting, Edwin S Y Chan, N Venketasubramanian, Christopher Chen, Bernard P L Chan, Michel Meyer Samama, Marie Germaine Bousser.   

Abstract

BACKGROUND AND
OBJECTIVE: Previous studies on Danqi Piantan Jiaonang (DPJ, NeuroAid), a traditional Chinese medicine, in stroke patients showed promising results. Our aim was to determine the safety of DPJ in normal subjects and stroke patients through a series of studies assessing its immediate and long-term effects, alone and in combination with aspirin, on hematological, hemostatic, and biochemical parameters.
METHODS: We conducted 3 studies from December 2004 to May 2006. Study 1 was a case series which recruited 32 healthy volunteers who were given 2 oral doses of 4 DPJ capsules (0.4 g/capsule) 6 h apart. Study 2 was a randomized controlled trial of 22 healthy volunteers who received either 1 oral dose of aspirin 300 mg alone or a combination of 1 dose of aspirin 300 mg and 2 doses of 4 DPJ capsules taken 6 h apart. For both studies 1 and 2, hemostatic parameters (prothrombin time, activated partial thromboplastin time, fibrinogen, platelet aggregation, D-dimer) were tested at baseline, and after 2 and 8 h. Study 3 was a case series which recruited 10 patients with recent ischemic stroke (within 7 days) who were given 4 DPJ capsules taken orally 3 times a day for 1 month. Blood tests for hemostatic, hematological (complete blood count), and biochemical parameters (glucose, creatinine, alanine aminotransferase, aspartate transaminase, C-reactive protein) were performed at baseline, and after 1 and 4 weeks.
RESULTS: Apart from the expected changes in platelet aggregation in subjects taking aspirin, no significant differences were detected in hemostatic parameters at baseline, and 2 and 8 h after oral intake of DPJ alone or in combination with aspirin. Likewise, no significant differences were observed in hematological, hemostatic, and biochemical parameters at baseline, and after 1 and 4 weeks of oral intake of DPJ.
CONCLUSION: DPJ does not significantly modify hematological, hemostatic, and biochemical parameters in normal subjects and stroke patients. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417963     DOI: 10.1159/000126919

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  10 in total

1.  A randomized trial to assess the long-term safety of NeuroAiD among Caucasian patients with acute ischemic stroke.

Authors:  Reza Bavarsad Shahripour; Ahmad Hemati; Ana Hosseinzadeh Maleki
Journal:  Chin J Integr Med       Date:  2014-04-02       Impact factor: 1.978

2.  Therapeutic efficacy of Neuro AiD™ (MLC 601), a traditional Chinese medicine, in experimental traumatic brain injury.

Authors:  Ming-Che Tsai; Ching-Ping Chang; Syue-Wei Peng; Kai-Sheng Jhuang; Yi-Hsien Fang; Mao-Tsun Lin; Thomas Chang-Yao Tsao
Journal:  J Neuroimmune Pharmacol       Date:  2014-10-21       Impact factor: 4.147

3.  Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  A A Harandi; R Abolfazli; A Hatemian; K Ghragozlee; M Ghaffar-Pour; M Karimi; S Shahbegi; H Pakdaman; M Tabasi; A L Tabatabae; A Nourian
Journal:  Stroke Res Treat       Date:  2011-06-21

4.  Spinal Cord Injury-Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury.

Authors:  Ramesh Kumar; Ohnmar Htwe; Azmi Baharudin; Mohammad Hisam Ariffin; Shaharuddin Abdul Rhani; Kamalnizat Ibrahim; Aishah Rustam; Robert Gan
Journal:  JMIR Res Protoc       Date:  2016-12-05

5.  The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia.

Authors:  C Widmann; C Gandin; A Petit-Paitel; M Lazdunski; C Heurteaux
Journal:  Sci Rep       Date:  2018-12-24       Impact factor: 4.379

6.  The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial.

Authors:  Christopher L H Chen; Purabi Reang Sharma; Boon Yeow Tan; Casuarine Low; Narayanaswamy Venketasubramanian
Journal:  Alzheimers Dement (N Y)       Date:  2019-01-23

7.  Danqi soft capsule prevents infarct border zone remodelling and reduces susceptibility to ventricular arrhythmias in post-myocardial infarction rats.

Authors:  Shiyu Ma; Jin Ma; Xiaoyi Mai; Xujie Zhao; Liheng Guo; Minzhou Zhang
Journal:  J Cell Mol Med       Date:  2019-06-24       Impact factor: 5.310

8.  Randomised, double-blind, placebo-controlled study investigating Safety and efficAcy of MLC901 in post-traUmatic bRAin Injury: the SAMURAI study protocol.

Authors:  Pavel Pilipenko; Anna Andreevna Ivanova; Yulia Vadimovna Kotsiubinskaya; Valery Feigin; Marek Majdan; Vera Naumovna Grigoryeva; Alexey Yevgenievich Khrulev
Journal:  BMJ Open       Date:  2022-04-13       Impact factor: 3.006

9.  The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients.

Authors:  Jose C Navarro; Mark C Molina; Alejandro C Baroque Ii; Johnny K Lokin
Journal:  Rehabil Res Pract       Date:  2012-12-13

10.  The NeuroAiD Safe Treatment (NeST) Registry: a protocol.

Authors:  Narayanaswamy Venketasubramanian; Ramesh Kumar; Lyna Soertidewi; Azizi Abu Bakar; Carine Laik; Robert Gan
Journal:  BMJ Open       Date:  2015-11-13       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.